Hints and tips:
Related Special Reports
...Eli Lilly and Vertex declined to comment on the talks....
...But he ruled out bidding for companies with potential obesity treatments, despite surging sales of weight loss and diabetes drugs sold by Novo Nordisk and Eli Lilly....
...David Ricks, Eli Lilly’s chief executive, said under a draft plan to cut market exclusivity protection from 10 to eight years, it might not be worth the industry pursuing treatments for chronic diseases...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...Eli Lilly has agreed to buy cancer biotech Point Biopharma for about $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price amid a severe cash crunch in the biotech industry....
...According to Dealogic, the outlay by Novo Nordisk and Eli Lilly compares to a total of $305mn that the entire pharmaceutical industry spent on acquisitions and partnerships in the field in the previous ten...
...The recent shift in tone has seen Warren Buffett’s Berkshire Hathaway and drugmaker Eli Lilly overtake Tesla in terms of market capitalisation....
...Big drugmakers are rushing to develop drugs that could compete in the anti-obesity market dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound....
...US drugmaker Eli Lilly is riding a wave of investor optimism and media hype about new treatments for two of the biggest public health problems: obesity and Alzheimer’s....
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
...Second-quarter results from Eli Lilly showed how quickly demand is increasing....
...These medications have enjoyed enormous success over the past year, leading to huge share price gains for their producers, Novo Nordisk and Eli Lilly....
...Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform...
...In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...That view was echoed by Tricia Bryan, a WeightWatchers member who has lost 17lbs since pairing the Core programme with a Clinic prescription for Eli Lilly’s Zepbound. “The medication is a tool....
...Lilly, Broadcom and JPMorgan....
...The Danish group and Eli Lilly dominate the fast-growing market for weight loss treatments that analysts have estimated could be worth as much as $140bn....
...Trading at around 9 times forward earnings, a fraction of peers Eli Lilly and Novo Nordisk....
...Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lilly’s Mounjaro and Zepbound, have incredible potential....
...JD Vargas, a partner at EQT, said the expected opening of large plants by companies such as Tesla, Albermarle, Eli Lilly, Chevron and BASF would add to waste infrastructure demand....
International Edition